Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Galderma S.A.
Combining biological insights with data science, the start-up emerges from stealth mode after two years of assembling its technology platform and R&D pipeline based on internal and external know-how.
Biopharma experts discuss at a summit core issues around ensuring that fast-paced digital acceleration does not jeopardize the overall experience of healthcare professionals. Clarity about customer needs/behaviors, embracing a fail-fast, learn-fast mindset and measuring customer experience were among the aspects touched upon.
The company will focus on developing its VenoValve system to treat chronic venous insufficiency and a second product for venous disease.
ICU Medical will pay about $500m in stock, $1.85bn in cash, and assume certain liabilities to acquire the medical division of Smiths Group. Smiths is also eligible for $100m in milestone payments from ICU Medical. The deal is better than the $2.3bn offer Smiths got from a subsidiary of private equity firm TA Associates earlier in August.
- OTC, Consumer
- Other Names / Subsidiaries
- CollaGenex Pharmaceuticals, Inc., Nestle S.A.
- Nestle Skin Health S.A.
- Spirig Pharma AG
- Q-Med AB